We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Cerebrospinal fluid camk2a levels at baseline predict long-term progression in multiple sclerosis.
- Authors
Sohaei, Dorsa; Thebault, Simon; Avery, Lisa M.; Batruch, Ihor; Lam, Brian; Xu, Wei; Saadeh, Rubah S.; Scarisbrick, Isobel A.; Diamandis, Eleftherios P.; Prassas, Ioannis; Freedman, Mark S.
- Abstract
Background: Multiple sclerosis (MS) remains a highly unpredictable disease. Many hope that fluid biomarkers may contribute to better stratification of disease, aiding the personalisation of treatment decisions, ultimately improving patient outcomes. Objective: The objective of this study was to evaluate the predictive value of CSF brain-specific proteins from early in the disease course of MS on long term clinical outcomes. Methods: In this study, 34 MS patients had their CSF collected and stored within 5 years of disease onset and were then followed clinically for at least 15 years. CSF concentrations of 64 brain-specific proteins were analyzed in the 34 patient CSF, as well as 19 age and sex-matched controls, using a targeted liquid-chromatography tandem mass spectrometry approach. Results: We identified six CSF brain-specific proteins that significantly differentiated MS from controls (p < 0.05) and nine proteins that could predict disease course over the next decade. CAMK2A emerged as a biomarker candidate that could discriminate between MS and controls and could predict long-term disease progression. Conclusion: Targeted approaches to identify and quantify biomarkers associated with MS in the CSF may inform on long term MS outcomes. CAMK2A may be one of several candidates, warranting further exploration.
- Subjects
MULTIPLE sclerosis; TANDEM mass spectrometry; CEREBROSPINAL fluid; NATALIZUMAB; DISEASE progression
- Publication
Clinical Proteomics, 2023, Vol 20, Issue 1, p1
- ISSN
1542-6416
- Publication type
Article
- DOI
10.1186/s12014-023-09418-9